Stabilis

Fluconazole



Noms commerciaux

Diflucan	Australie, Autriche, Belgique, Canada, Croatie, Danemark, Espagne, Etats Unis d'Amérique, Finlande, Grande Bretagne, Italie, Luxembourg, Norvège, Pays bas, Pologne, Portugal, Russie, Slovénie, Suède, Suisse, Vénézuela
Elazor	Italie
Exomax	Italie
Flucand	Arabie Saoudite, Tunisie
Flucofex	Turquie
Fluconax	Croatie
Fluconazol	Allemagne, Brésil, Luxembourg
Fluconazole	Canada
Fluconovag	Argentine
Flumycon	Pologne
Fungustatin	Grèce
Loitin	Espagne
Lumen	Turquie
Mycomax	Pologne
Mycosyst	Pologne
Triflucan	France, Turquie

Stabilité des solutions

		1 mg/ml	25°C		24			257
	RL	1 mg/ml	25°C		24			257
P I		2 mg/ml	4°C		15			604

Stabilité en mélange

		2 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
		0,5 & 1,5 mg/ml	24°C		Aminophylline : 1 & 2 mg/ml	3	262

		0,5 & 1,5 mg/ml	23°C-25°C		Tacrolimus : 5 & 20 µg/ml	3		1421
		2 mg/ml	23°C		Paclitaxel : 0,3 & 1,2 mg/ml	4		151
		1 mg/ml	25°C		Heparin sodium : 100 UI/ml	24		257
		1 mg/ml	25°C		Morphine sulfate : 0,5 mg/ml	24		257
		1 mg/ml	25°C		Theophylline : 0,8 mg/ml	72		257
		1 mg/ml	25°C	?	Filgrastim : 40 µg/ml	4		104
	RL	2 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
	0.45	2 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		1,75 mg/ml	24°C			2		286
?		1,3 mg/ml	22°C-28°C	?	Daptomycin : 6,3 mg/ml	2		1937

Compatibilités

		Fluconazole : 2 mg/ml		1415
		Fluconazole : 2 mg/ml Aciclovir sodium : 10 mg/ml	∅	256
		Fluconazole : 2 mg/ml		3967
		Fluconazole : 2 mg/ml Aciclovir sodium : 10 mg/ml		496
		Fluconazole : 2 mg/ml Aldesleukin : 0.0338 MUI/ml		36
		Fluconazole : 2 mg/ml Allopurinol sodium : 3 mg/ml		307
		Fluconazole : 2 mg/ml Amifostine : 10 mg/ml		3
		Fluconazole : 2 mg/ml Amikacin sulfate : 20 mg/ml		496
		Fluconazole : 2 mg/ml Amikacin sulfate : 5 mg/ml	∅	256
		Fluconazole : 0.5 & 1.5 mg/ml Aminophylline : 1 & 2 mg/ml		262
		Fluconazole : 2 mg/ml Aminophylline : 25 mg/ml		496
		Fluconazole : 2 mg/ml Amiodarone hydrochloride : 6 mg/ml	0.45 2.5	1611
		Fluconazole : 2 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Fluconazole : 2 mg/ml Amphotericin B : 0.1 mg/ml	∅	256
		Fluconazole : 2 mg/ml Amphotericin B : 5 mg/ml		496

		Fluconazole : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Fluconazole : 2 mg/ml Ampicillin sodium : 20 mg/ml		496
		Fluconazole : 2 mg/ml Ampicillin sodium - sulbactam sodium : 60 mg/ml		496
		Fluconazole : 2 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Fluconazole : 2 mg/ml Aztreonam : 40 mg/ml		496
		Fluconazole : 2 mg/ml Aztreonam : 40 mg/ml		99
		Fluconazole : 2 mg/ml Benztropine mesylate : 1 mg/ml		496
		Fluconazole : 2 mg/ml Bivalirudin : 5 mg/ml		1713
		Fluconazole : 2 mg/ml Caffeine : 10 mg/ml	∅	3964
		Fluconazole : 2 mg/ml Calcium gluconate : 100 mg/ml		496
		Fluconazole : 1 mg/ml		4440
		Fluconazole : 2 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Fluconazole : 2 mg/ml Cefazolin sodium : 40 mg/ml		496
		Fluconazole : 2 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Fluconazole : 2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Fluconazole : 2 mg/ml Cefotaxime sodium : 20 mg/ml		496
		Fluconazole : 2 mg/ml Cefoxitin sodium : 40 mg/ml		496
		Fluconazole : 2 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Fluconazole : 2 mg/ml	RL	4603
		Fluconazole : 2 mg/ml Cefazolin sodium : 20 mg/ml	∅	256
		Fluconazole : 2 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Fluconazole : 2 mg/ml Cefpirome sulfate : 50 mg/ml	0.45	280
		Fluconazole : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Fluconazole : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Fluconazole : 2 mg/ml Ceftazidime : 40 mg/ml	∅	256
		Fluconazole : 2 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Fluconazole Ceftazidime		3883

		Fluconazole : 2 mg/ml Ceftazidime : 20 mg/ml		496
		Fluconazole : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Fluconazole : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Fluconazole : 2 mg/ml Ceftriaxone disodium : 40 mg/ml		496
		Fluconazole Ceftriaxone disodium		3523
		Fluconazole		3985
		Fluconazole : 2 mg/ml Ceftazidime : 125 mg/ml		2141
		Fluconazole : 0.5 & 1.75 mg/ml		286
		Fluconazole : 2 mg/ml Cefuroxime sodium : 30 mg/ml		496
		Fluconazole : 2 mg/ml Chloramphenicol sodium succinate : 20 mg/ml		496
		Fluconazole : 2 mg/ml Chlorpromazine hydrochloride : 25 mg/ml		496
		Fluconazole : 2 mg/ml Cimetidine hydrochloride : 150 mg/ml		496
		Fluconazole : 2 mg/ml Cimetidine hydrochloride : 1 & 2 mg/ml		255
		Fluconazole : 2 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Fluconazole : 2 mg/ml Clindamycin phosphate : 12 mg/ml	∅	256
		Fluconazole : 2 mg/ml Clindamycin phosphate : 24 mg/ml		496
		Fluconazole : 2 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Fluconazole Daptomycin		2271
		Fluconazole : 2 mg/ml		3379
		Fluconazole : 2 mg/ml Co-trimoxazole : 16 mg/ml		496
		Fluconazole : 2 mg/ml Co-trimoxazole : 0.8/4 mg/ml	∅	256
		Fluconazole : 2 mg/ml		301
		Fluconazole : 1 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Fluconazole : 1,3 mg/ml Daptomycin : 6,3 mg/ml		1937
		Fluconazole Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Fluconazole : 2 mg/ml Defibrotide : 8 mg/ml		3728
		Fluconazole : 2 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		496

		Fluconazole : 2 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Fluconazole : 2 mg/ml Diazepam : 5 mg/ml		496
		Fluconazole : 2 mg/ml Digoxin : 250 µg/ml		496
		Fluconazole : 2 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Fluconazole Dimenhydrinate		2087
		Fluconazole : 2 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		496
		Fluconazole : 2 mg/ml Dobutamine hydrochloride : 2 mg/ml		255
		Fluconazole : 2 mg/ml Docetaxel : 0.9 mg/ml		1754
		Fluconazole : 2 mg/ml Dopamine hydrochloride : 1,6 mg/ml		255
		Fluconazole : 2 mg/ml Doripenem : 5 mg/ml		2262
		Fluconazole : 2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Fluconazole : 2 mg/ml Droperidol : 2.5 mg/ml		496
		Fluconazole : 2 mg/ml Eravacycline : 0,6 mg/ml		4434
		Fluconazole : 2 mg/ml Erythromycin lactobionate : 20 mg/ml		496
		Fluconazole : 2 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Fluconazole : 2 mg/ml Famotidine : 10 mg/ml		496
		Fluconazole : 2 mg/ml Famotidine : 2 mg/ml		215
		Fluconazole : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Fluconazole : 2 mg/ml Filgrastim : 40 µg/ml		104
		Fluconazole : 2 mg/ml Filgrastim : 30 µg/ml		244
		Fluconazole : 2 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Fluconazole : 2 mg/ml Folinate calcium : 10 mg/ml		496
		Fluconazole : 2 mg/ml Foscarnet sodium : 24 mg/ml		496
		Fluconazole : 2 mg/ml Furosemide : 10 mg/ml		496
		Fluconazole : 2 mg/ml Gallium nitrate : 1 mg/ml		91
		Fluconazole : 2 mg/ml Ganciclovir sodium : 50 mg/ml		496

		Fluconazole : 2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Fluconazole : 2 mg/ml Gentamicin sulfate : 1 mg/ml		256
		Fluconazole : 2 mg/ml Gentamicin sulfate : 4 mg/ml		496
		Fluconazole : 2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Fluconazole : 2 mg/ml Haloperidol lactate : 5 mg/ml		496
		Fluconazole : 2 mg/ml Heparin sodium : 50 UI/ml		317
		Fluconazole : 2 mg/ml Heparin sodium : 1000 UI/ml		496
		Fluconazole : 2 mg/ml Hetastarch : 60 mg/ml		1721
		Fluconazole : 2 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml		496
		Fluconazole : 2 mg/ml Imipenem - cilastatin sodium : 10 mg/ml		496
		Fluconazole : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Fluconazole : 2 mg/ml Linezolid : 2 mg/ml		1925
		Fluconazole : 2 mg/ml Lorazepam : 0.33 mg/ml		186
		Fluconazole : 2 mg/ml Melphalan : 0.1 mg/ml		169
		Fluconazole : 2 mg/ml Meropenem : 1 >> 50 mg/ml		266
		Fluconazole : 2 mg/ml Meropenem : 50 mg/ml		4319
		Fluconazole : 2 mg/ml Metoclopramide hydrochloride : 5 mg/ml		496
		Fluconazole : 2 mg/ml Metronidazole : 5 mg/ml		496
		Fluconazole : 2 mg/ml Metronidazole : 5 mg/ml		256
		Fluconazole : 2 mg/ml Midazolam hydrochloride : 5 mg/ml		496
		Fluconazole : 2 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Fluconazole : 1 mg/ml Morphine sulfate : 1 mg/ml		62
		Fluconazole : 2 mg/ml Morphine sulfate : 25 mg/ml		496
		Fluconazole : 2 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Fluconazole : 2 mg/ml Nafcillin sodium : 20 mg/ml		496
		Fluconazole : 2 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408

		Fluconazole : 2 mg/ml Nitroglycerin : 0,2 mg/ml		255
		Fluconazole : 2 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Fluconazole : 2 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Fluconazole : 2 mg/ml Oxacillin sodium : 40 mg/ml		496
		Fluconazole : 2 mg/ml Paclitaxel : 0,3 & 1,2 mg/ml		151
		Fluconazole : 2 mg/ml Paclitaxel : 1.2 mg/ml		248
		Fluconazole : 2 mg/ml Pancuronium bromide : 0,5 mg/ml		255
		Fluconazole Pantoprazole sodium		2090
		Fluconazole : 2 mg/ml Paracetamol : 10 mg/ml		4742
		Fluconazole : 2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Fluconazole : 2 mg/ml Penicillin G potassium : 0.1 MUI/ml		496
		Fluconazole : 2 mg/ml Pentamidine isetionate : 6 mg/ml		496
		Fluconazole : 1 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Fluconazole : 2 mg/ml Phenytoin sodium : 50 mg/ml		496
		Fluconazole : 1 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Fluconazole : 2 mg/ml Piperacillin sodium : 80 mg/ml	∅	256
		Fluconazole : 2 mg/ml Piperacillin sodium : 80 mg/ml		496
		Fluconazole : 2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Fluconazole : 2 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Fluconazole : 2 mg/ml Prochlorperazine edysilate : 5 mg/ml		496
		Fluconazole : 2 mg/ml Promethazine hydrochloride : 50 mg/ml		496
		Fluconazole : 2 mg/ml Propofol : 10 mg/ml	∅	300
		Fluconazole : 2 mg/ml Propofol		660
		Fluconazole : 2 mg/ml Quinupristine/dalfopristine : 2 mg/ml		1513
		Fluconazole : 2 mg/ml Ranitidine hydrochloride : 0,5 & 2 mg/ml		18
		Fluconazole : 2 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59

		Fluconazole : 2 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Fluconazole : 2 mg/ml Sargramostim : 10 µg/ml		335
		Fluconazole : 1 mg/ml Sodium citrate : 40 mg/ml		3186
		Fluconazole : 0,5 & 1,5 mg/ml Tacrolimus : 5 & 20 µg/ml		1421
		Fluconazole : 2 mg/ml Tacrolimus : 1000 µg/ml		479
		Fluconazole : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Fluconazole : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Fluconazole : 2 mg/ml Temocilline : 83.33 mg/ml		2231
		Fluconazole : 2 mg/ml Teniposide : 0.1 mg/ml		905
		Fluconazole : 2 mg/ml Theophylline : 1,6 mg/ml		255
		Fluconazole : 2 mg/ml Theophylline : 4 mg/ml	∅	317
		Fluconazole : 2 mg/ml Thiamine hydrochloride : 0.2 mg/ml		4254
		Fluconazole : 2 mg/ml Thiopental sodium : 25 mg/ml		3767
		Fluconazole : 2 mg/ml Thiotepa : 1 mg/ml		249
		Fluconazole : 2 mg/ml Ticarcillin / clavulanic acid : 60 mg/ml		496
		Fluconazole : 2 mg/ml Tobramycin sulfate : 40 mg/ml		496
		Fluconazole : 2 mg/ml Vancomycin hydrochloride : 20 mg/ml		496
		Fluconazole : 2 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Fluconazole : 2 mg/ml Vasopressin : 0.2 UI/ml		2017
		Fluconazole : 2 mg/ml Vecuronium bromide : 1 mg/ml		255
		Fluconazole : 2 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Fluconazole : 2 mg/ml Zidovudine : 10 mg/ml		496

Voie d'administration

Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
18	Revue	Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 391-394.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Revue	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
151	Revue	Burm JP, Choi JS, Jhee SS, Chin A, Ulrich RW, Gill MA. Stability of paclitaxel and fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 2704-2706.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.

182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
255	Revue	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
256	Revue	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
257	Revue	Hunt-Fugate AK, Hennessey CK, Kazarian CM. Stability of fluconazole in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1186-1187.
262	Revue	Johnson CE, Jacobson PA, Pillen HA, Woycik CL. Stability and compatibility of fluconazole and aminophylline in intravenous admixtures. Am J Hosp Pharm 1993 ; 50: 703-706.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
280	Revue	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
286	Revue	Couch P, Jacobson P, Johnson CE. Stability of fluconazole and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 1992 ; 49: 1459-1462.

299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.

1421	Revue	Johnson CE, Truong NM. Stability and compatibility of tacrolimus and fluconazole in 0.9% sodium chloride. J Am Pharm Assoc 1999 ; 39: 505-509.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1513	Laboratoire	Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit Monarch Pharmaceuticals Ireland 2006
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	Revue	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Revue	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.

2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratoire	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3186	Revue	Bryan Dotson B, Churchwell MD. Physical compatibility of 4% sodium citrate with 23.4% sodium chloride, fluconazole, and micafungin. Am J Health-Syst Pharm 2011 ; 68:377-378.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.

3523	Laboratoire	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	Revue	Staven V, Herra I, Wang S, Grönlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3985	Poster	Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M. Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro. Hopipharm Congress 2017 - Nancy 2017
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Fluconazole



Stabilité des préparations

		1 mg Diflucan®	Eau purifiée >> 1 ml	23°C		15			2527
		1 mg Diflucan®	Eau purifiée >> 1 ml	45°C		15			2527
		1 mg Diflucan®	Eau purifiée >> 1 ml	4°C		15			2527
		2500 mg ® = ?	Acésulfame potassique 100 mg Glycosides de stéviol 95% 100 mg Arôme orange 1 mL Suspendit® >> 50 mL	2-8°C		182			4107
		2500 mg ® = ?	Acésulfame potassique 100 mg Glycosides de stéviol 95% 100 mg Arôme orange 1 mL Suspendit® >> 50 mL	23-27°C		182			4107

Bibliographie

	Type	Source
2527	Revue	Yamreudeewong W, Lopez-Anaya A, Rappaport H. Stability of fluconazole in an extemporaneously prepared oral liquid Am J Hosp Pharm 1993 ; 50: 2366-2367.
4107	Revue	Ip K, Shan A, Carvalho M, Baker S, Banov D. Physicochemical Stability of Extemporaneously Prepared Oral Suspension of Fluconazole 50 mg/mL in SuspendIt. Pharmaceutical Technology in Hospital Pharmacy 2018

Dictionnaire

	Antifongique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Glucose 5%		Lumière
	Heure	RL	Ringer lactate
	Elastomère en polyisoprène		Chlorure de sodium 0,9%
	A l'abri de la lumière		Jour
	Stabilité en mélange		Solvant
	Molécule		NaCl 0,9% ou glucose 5%
?	Non précisée		Chlorure de sodium 0,45%
	Nutrition parentérale (mélange binaire)	?	Non précisé
	Compatibilités		Compatible
	Nutrition parentérale (mélange ternaire)	∅	Aucun
	NaCl 0,45% Glucose 2,5%		Turbidité en 1 heure
	Incompatible		Précipitation immédiate
	Turbidité immédiate		Eau pour préparation injectable
	Changement de couleur		Incompatibilité non précisée
	Dégagement gazeux		Précipitation en 1 heure
	Solvant spécifique		Précipitation en 4 heures
	Instabilité de l'émulsion à 6 heures		Voie d'administration
	Perfusion intraveineuse		Bibliographie
	Solution buvable		Stabilité des préparations
	Origine		Excipient
	Comprimés		Flacon plastique
	Poudre		Dictionnaire